9:05   Ligand and Palvella Therapeutics 2025-2026 Financial and Pipeline Reports 5:57   LIGAND Pharmaceuticals Acquisition: My Take on the CVRs 7:38   Ligand Pharmaceuticals (LGND) Stock Analysis 2026: XOMA Deal, $289 Target & Royalty Growth 4:54   Ligand CEO Explains Royalty Aggregators 2:04   Ligand's Investment Philosophy 6:21   I Ran the Numbers on the Biotech Stock Up 200% - Here's What I Found 5:05   Ligand Pharmaceuticals CEO Todd Davis Explores Catalysts to Drive Biotech Performance 4:25   ligand efficiency & heavy atoms in drugs 7:40   Do not buy Ligand Pharmaceuticals stock before seeing this video!📈 (LGND Stock Analysis) 4:01   Ligand Pharmaceuticals' CEO Todd David Discusses Gene Therapy & Castle Creek Biosciences 12:52   Ligand Pharmaceuticals Inc. 1:05   Ligand Pharmaceuticals 4:03   Ligand CEO on how company's helping find a cure for the coronavirus 5:09   target-based, ligand-based, & phenotype-based drug discovery 0:28   🔴 Ligand Pharmaceuticals Inc. LGND Stock Trading Facts 🔴